Tolera raises $5.5M for PhIII SPA; Enanta touts role in closely watched hep C cocktail;

Conversation on Twitter :

 @FierceBiotech: Scientists produced stem cells from cadaver scalp tissue. Item | Follow @FierceBiotech

 @JohnCFierce: Looks like Samsung is getting a taste of just how devilishly hard it can be to develop drugs. More | Follow @JohnCFierce

 @RyanMFierce: Charles River is touting a 3-year strategic deal with AstraZeneca, which is outsourcing across the globe. More | Follow @RyanMFierce

> The European Commission is providing researchers with €6 million ($7.8 million) to advance NovImmune's monoclonal antibody called NI-0501 for treating the immune disorder known as hemophagocytic lymphohistiocytosis. Article

>Kalamazoo, MI-based biotech Tolera Therapeutics has raised $5.5 million in a Series B-3 found of financing as the company works on submitting a Phase III special protocol assessment for its biologic compound for use in kidney transplantations. Item

> Enanta Pharmaceuticals (a 2012 Fierce 15 company) highlighted the role of its compound, ABT-450, in a cocktail therapy against hepatitis C that its partner Abbott Laboratories ($ABT) is advancing into Phase III development. Release

Medical Device News

 @FierceMedDev: The FDA has slapped its most serious label on Accutron's voluntary flowmeter recall. More | Follow @FierceMedDev

 @MarkHFierce: New device company Cibiem launches with $10M series A. More | Follow @MarkHFierce

 @DamianFierce: AstraZeneca's inked a deal with another CRO, picking Charles River to help speed along its pipeline. More | Follow @DamianFierce

> Quest lowers outlook after Q3 profit drop. Story

> For some, Intuitive Surgical's Q3 20% revenue jump isn't enough. Article

> Analyst: China is primed for a medical device boom. News

Pharma News

@FiercePharma: Our latest ranking: 10 Largest Settlements and Judgments. Includes those big state deals. More | Follow @FiercePharma

> Abbott's drug sales tick upward as AbbVie spinoff looms. Story

> Sanofi, Coca-Cola team up on 'Beautific' drinks. Article

> Pfizer's bid to forestall Chantix trial fails. News

Biomarkers News

> Gene variants increase bipolar risk. Article

> Protein marker could cut cost of cancer screening. More

> Gene variant in donated kidneys could mark survival. Report

> Endocyte uses vitamin receptor to tag lung cancer. Story

Drug Delivery News

> Simple anti-HIV vaginal ring delivers three months of protection. Story

> Over the moon? NASA develops motion sickness nasal spray. Item

> Why shape matters in gene delivery. More

> Hiding in plain sight: Using red blood cell proteins to deliver drugs. Article

> Unilife announces new eye delivery platforms. News

And Finally… Lance Armstrong is stepping down as chairman of his cancer charity Livestrong and has lost his Nike deal amid doping allegations against the cycling legend. Article

 

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.